GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Institutional Ownership

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Institutional Ownership : 19.45% (As of Apr. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Chugai Pharmaceutical Co's institutional ownership is 19.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Chugai Pharmaceutical Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Chugai Pharmaceutical Co's Float Percentage Of Total Shares Outstanding is 0.00%.


Chugai Pharmaceutical Co Institutional Ownership Historical Data

The historical data trend for Chugai Pharmaceutical Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Institutional Ownership Chart

Chugai Pharmaceutical Co Historical Data

The historical data trend for Chugai Pharmaceutical Co can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-03-31
Institutional Ownership 19.01 19.31 19.35 19.49 19.53 19.56 19.51 19.33 19.36 19.45

Chugai Pharmaceutical Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines